Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €23.22 EUR
Change Today -0.235 / -1.00%
Volume 35.6K
IBAB On Other Exchanges
EN Brussels
As of 11:35 AM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

ion beam applications (IBAB) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - €25.48
52 Week Low
08/18/14 - €10.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ION BEAM APPLICATIONS (IBAB)

Related News

No related news articles were found.

ion beam applications (IBAB) Related Businessweek News

No Related Businessweek News Found

ion beam applications (IBAB) Details

Ion Beam Applications, SA, a medical technology company, focuses on providing solutions for the diagnosis and treatment of cancer in Belgium, the United States, and internationally. It operates through two segments, Proton Therapy and Particle Accelerators, and Dosimetry. The Proton Therapy and Particle Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or single photon emission computed tomography radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides measurement and quality assurance instruments for radiotherapy and medical imaging to enable healthcare professionals to verify that equipment administers the planned dose to the targeted area. Ion Beam Applications, SA was founded in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

1,071 Employees
Last Reported Date: 05/1/15
Founded in 1986

ion beam applications (IBAB) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: €639.5K
Compensation as of Fiscal Year 2014.

ion beam applications (IBAB) Key Developments

IBA Extends Collaboration Agreement with Guangdong Hengju Medical

Ion Beam Applications SA, or IBA, a medical technology company, has signed an extension to the collaboration agreement with Guangdong Hengju Medical Technologies Co. Limited for two additional gantry treatment rooms. This binding agreement for two additional gantry treatment rooms, equipped with the next generation Pencil Beam Scanning capability, is worth approximately EUR 20 million to IBA. In December 2014, IBA signed its first collaboration agreement with Guangdong Hengju Medical Technologies Co. Limited to jointly install the first proton therapy system in South China. This agreement is worth approximately EUR 30 million to IBA. With a total of three rooms planned, the facility is expected to open in 2017.

Ion Beam Applications S.A. Partners with Proton Partners International to Install Three Proton Therapy Solutions in UK

Ion Beam Applications S.A. or IBA has signed three separate binding term sheets, with Proton Partners International, or PPI, to install three ProteusONE compact proton therapy solutions in private clinics in the UK. Each term sheet covers delivery of the ProteusONE equipment, including next generation Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT) capabilities, and a ten-year maintenance agreement. The typical end-user price for a ProteusONE system with such a maintenance contract is between EUR 35 and 40 million. These three centers will be the eighth, ninth and tenth installations of IBA's compact single-room proton therapy solution and are expected to treat the first patients in 2017. The proton therapy center in Newport will treat patients from Wales, the south-west of England and the Midlands, and the center in Newcastle will treat patients from the North of England. The location of the third center will be announced at a later date. These three projects follow the framework agreement that IBA and Philips signed in September 2014 to advance the diagnosis and treatment of cancer and demonstrate the efficiency of the collaboration between the two organizations.

Ion Beam Applications S.A. Signs Purchase Agreement with University of Chicago

Ion Beam Applications S.A. has signed a purchase agreement with the University of Chicago to install the company's Cyclone 18 and Synthera platform. This contract further strengthens IBA's worldwide leading position in radiopharmacy solutions. IBA is wining important contracts in all regions (Asia, Europe, North America, Russia, and the Middle East) further establishing IBA's position as the leader in medium and high energy cyclotrons. The majority of the cyclotrons sold are IntegraLab solutions which combine equipment and services for the establishment of radiopharmaceutical production centers.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBAB:BB €23.22 EUR -0.235

IBAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Analogic Corp $76.95 USD -0.60
Balchem Corp $55.30 USD -0.88
Mallinckrodt PLC $119.32 USD -0.31
Sumitomo Heavy Industries Ltd ¥683.00 JPY +5.00
Varian Medical Systems Inc $85.81 USD -0.28
View Industry Companies

Industry Analysis


Industry Average

Valuation IBAB Industry Range
Price/Earnings 29.5x
Price/Sales 2.7x
Price/Book 5.5x
Price/Cash Flow 25.5x
TEV/Sales 2.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ION BEAM APPLICATIONS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at